Title: Sex differences in the associations of human milk oligosaccharides with height and

weight in breastfed Ugandan children.

Authors: Tonny Jimmy Owalla¹, Victor Irungu Mwangi², Sara Moukarzel^{3,4}, Emmanuel Okurut¹,

Chloe Yonemitsu³, Lars Bode^{3, 4}, Thomas G. Egwang¹

Authors Affiliations: ¹Med Biotech Laboratories, Kampala, Uganda; ²Programa de Pós-

Graduação em Medicina Tropical, Universidade do Estado do Amazonas (UEA), Manaus, AM,

Brazil; ³Department of Pediatrics, Division of Neonatology, University of California San Diego,

La Jolla, California, United States of America; ⁴Larsson-Rosenquist Foundation Mother-Milk-

Infant Center of Research Excellence (MOMI CORE), University of California San Diego, La

Jolla, California, United States of America.

Abstract

Background & Objective: Human milk oligosaccharides (HMOs) have been associated with

several child growth metrics, but there was no difference in the associations according to child sex.

Here, we present clinic-based cross-sectional data on the relationship between specific HMOs in

the milk of Ugandan mothers and growth in their breastfed children as a group and as males and

females separately.

Method: Human milk samples were manually collected from 127 lactating mothers. Levels of

human milk oligosaccharides (HMOs) were analyzed by high-performance liquid chromatography

(HPLC). Children's weight and length were measured using a portable digital scale and length

board, respectively. Weight-for-age (WAZ), height-for-age (HAZ) and weight for height (WHZ)

Z scores were calculated. The relationships between HMOs and untransformed weights and

heights and between WAZ, HAZ and WHZ subcategories were analyzed for all children and for

males and females separately by Spearman's correlation and Kruskal-Wallis and Mann-Whitney

U tests.

Results: There were positive and negative correlations between the concentrations of specific

HMOs and the heights and weights of children according to mothers' secretor status. Tall infant

stature was associated with higher concentrations of 6'SL, LSTc, DFLNH, DSLNH, LNnT and

total HMOs in secretor or nonsecretor mothers; short infant stature was associated with higher

concentrations of 3FL and DFLac; overweight was associated with higher concentrations of 6'SL,

LSTc and LNnT in secretor and nonsecretor mothers; and normal weight was associated with

higher concentrations of 3'FL. The associations between maternal HMO levels and childrens

heights and weights or between the LAZ, WAZ and WHZ subcategories significantly differed

between male and female children.

Conclusions: There are sex differences in the associations between high concentrations of some

HMOs and stature and weight in Ugandan children born to secretor and nonsecretor mothers.

Highlights

This study showed that some HMOs are associated with child growth metrics in a sex-

specific pattern.

Four HMOs (3FL, DSLNT, DFLac, and 3'SL) were positively correlated with the

height/length of the children.

There were significant positive correlations between height/length and 3FL and DSLNT in

only female children and between height/length and DFLac in only male children.

DSLNT, DFLac and LSTb were positively correlated with weight in female and male children

respectively.

Kevwords: HMOs, sex specific, growth, weight, height, children.

Plain Language Summary

Human milk oligosaccharides (HMOs) have been associated with growth parameters of children in the Americas, Europe and Asia. Only two such studies have been conducted in Africa. None of the studies investigated the relationship between child sex and HMO composition and growth interactions. We examined the relationship between 19 well-characterized HMOs and growth metrics and also dissected the data by infant sex. Our results show a positive correlation between some HMOs and growth indices in either female or male children only. This highlights the impact of sex differences in the relationship between specific HMOs and growth measures in children. This evidence, if validated, could inform future nutritional interventions involving combinations of HMOs as food supplements that are equally effective for both male and female children.

Background

Human milk contains an assortment of nutrients and bioactive molecules [1] and constitutes the best source of nutrition for infants, especially during the first 6 months of life [2,3]. Human milk components provide nourishment and play important developmental and protective functions. Compared with breastfed infants, nonbreastfed infants and children have a 14-fold greater risk of all-cause mortality and 8.6-fold higher infection-related mortality [2]. The benefits of breastfeeding can be partly attributed to human milk oligosaccharides (HMOs), a family of more than 150 nondigestible unconjugated carbohydrate molecules and the third most abundant biomolecule in human milk [4]. HMOs contain lactose at the reducing end that can be elongated by one or more disaccharides, such as N-acetyl-glucosamine and galactose [4,5]. Either lactose alone or elongated HMOs can be fucosylated at alpha-1-2/3/4-linkages and/or sialylated at alpha-2-3/6-linkages to form a variety of structurally distinct HMOs [4,5].

There is strong evidence that HMOs play a critical role in protecting children against infection through modulation of the gut microbiota and the immune system [6] and by serving as decoy

receptors that block the epithelial attachment of various classes of pathogens [4,7,8]. These HMO effects are composition- and structure-specific [6,9]. Population-based prospective studies of mother–infant pairs showed that maternal milk containing high levels of specific α1-2-linked fucosyloligosaccharides was associated with a reduced risk of diarrhea from Campylobacter, cholera, and stable toxins of enteropathogenic *Escherichia coli* in breastfed children [10]. Infections caused by viral diarrhea pathogens such as norovirus and rotavirus diarrhea occurred less often in children whose mothers' milk contained high levels of specific fucose-bound and sialic acid-bound oligosaccharides [11]. Remarkably, Lactodifucotetraose (LDFT) inhibited the release of proinflammatory proteins RANTES and sCD40L and platelet-induced inflammation [12], while 2'FL reduced mucosal-associated inflammation [13] in breastfed children. A clinical trial of 2'FL supplementation in infant formula confirmed its anti-inflammatory activity [14]. In addition to known anti-infective and anti-inflammatory functions, HMOs, in general, and sialic acid-bound HMOs, such as 3'SL and 6'SL, in particular, play significant roles in cognitive and brain development [15,16,17,18,19].

Studies in various countries have demonstrated an association between HMO concentrations or uptake and growth in children [20,21,22,23,24,25]. Lagstrom et al. (2020) showed that the concentrations of lacto-N-neo-tetraose (LNnT) and 2'FL were inversely and directly associated with height and weight, respectively, among children of Finnish secretor mothers [20]. In USA mother—infant dyads, lacto-N-fucopentaose I (LNFPI) was associated with lower infant weight, whereas disialyl-lacto-N-tetraose (DSLNT) and LNFPII were associated with greater fat mass [21]. Infant intakes of 3-fucosyllactose, 3'-sialyllactose (3'SL), 6'-sialyllactose (6'SL), DSLNT, disialyllacto-N-hexaose (DSLNH), and total sialylated HMOs were positively associated with infant growth over the first 6 months of life [22]. A Gambian study involving 33 mother—infant pairs concluded that 3'SL was a good indicator of infant weight-for-age [23], and several individual HMOs were associated with growth and development in a large study involving more

than 600 Malawian mother–infant pairs [24]. Commercially available HMOs in infant formula provided growth benefits comparable to those of breastfeeding in studies carried out in non-African countries [26,27,28].

There is a paucity of studies conducted in Africa that have investigated the relationship between HMOs and growth in breastfeeding children, and the outcomes of these studies are contradictory [23,24]. It was of interest to investigate the relationship between specific HMOs in the milk of Ugandan mothers and growth outcomes in their breastfed children. Here, we report on sexdependent associations between various HMOs and growth in breastfed Ugandan children.

Methods

Study design and population

The study population was a subset of a cohort of 400 mother—child pairs under 5 years old who were participating in a prospective longitudinal study investigating the effectiveness of a malaria vector control intervention in Abwokodia Parish, Katakwi district in northeastern Uganda. Details of the study site have been reported elsewhere [29]. This breast milk substudy involved a clinic-based cross-sectional survey of breastfeeding mother—infant pairs. All breastfeeding infants less than two years old and their respective breastfeeding mothers were considered eligible for the study upon consent by one or both parents, as applicable. One hundred and twenty-seven (127) breastfeeding mother—infant pairs were identified and included in the study.

Participant recruitment and anthropometric measurements

The study was conducted in March 2018. Mothers of all breastfeeding children who were participating in an ongoing longitudinal study were mobilized by a social scientist with the help of village health teams. Mother—child pairs visited the study clinic at St. Anne Health Center III for screening and enrollment. The objectives of the study were explained to the mothers, and informed consent was obtained. Milk samples were collected from consenting mothers. Child weight and

length and other anthropometric data for both mothers and children were measured using a portable digital scale (Seca 334) and length board (Seca 417), respectively.

Human milk sampling and treatment

A single 5-mL sample of human milk was collected from each lactating mother by manual expression with the help of a senior midwife who is an experienced lactation counsellor. Milk samples were collected into sterile 50-mL Falcon tubes and immediately frozen in dry ice. Milk samples were subsequently transported on dry ice to Med Biotech Laboratories in Kampala, where they were stored at -20°C before being air-freighted on dry ice to the University of California San Diego for HMO analysis.

HMO Extraction, Analysis, and Secretor Status Determination

Analysis of 19 well-characterized and most abundant HMOs was performed at the University of California, San Diego, as previously described [30]. Briefly, human milk samples were analyzed by HPLC after fluorescent derivatization. Raffinose was added to each milk sample as an internal standard for absolute quantification. The total concentration of HMOs was calculated as the sum of the specific oligosaccharides detected. The proportion of each HMO per total HMO concentration was calculated. The maternal phenotypic secretor status was determined by the relative abundance (secretor) or near absence (nonsecretor) of 2'FL and LNFP-I in the respective milk samples.

Statistical analyses

The weight and height of each infant was used to calculate weight-for-age (WAZ), weight-for-length (WFL) and height-for-age (HAZ) Z scores based on the standards of the World Health Organization [31]. These scores were also grouped into categorical variables. Height was subcategorized as short, normal or tall, while weight was subcategorized as underweight, normal

or overweight. Statistical analysis was performed using GraphPad Prism version 9.0.2 and STATA version 15. The Shapiro–Wilk test was used to evaluate the distribution of variables, including oligosaccharide concentrations. Nonparametric comparisons were made using the Mann–Whitney U test for paired samples or the Kruskal–Wallis test for groups. Exploratory analyses were performed to compare median oligosaccharide concentrations according to children's LAZ, WAZ and WHZ subcategories. The results are presented as box-plot graphs. Correlations between the oligosaccharide concentrations and the children's weight or height were assessed using the Spearman rank test with 95% confidence intervals. Significance was defined as a *P* value less than .05.

Results

Characteristics of the study participants

The study population comprised 127 breastfeeding mother—child pairs from Katakwi District in northeastern Uganda. The mothers had a mean age of 26.6 years (range 15-46), with a postpartum mean BMI of 23.3 kg/m² (18.7-31.8). Most of the mothers were multiparous (> 78%) and had breastfed for 3-103 weeks. The mean age, weight, and height/length of the children were 46 weeks (range 3-110), 8.8 kg (range 5-16), and 70.5 cm (range 50-98), respectively, and 52% were females.

Correlation between HMO concentrations and heights of all children

We undertook Spearman's correlation analysis to assess the effect of specific HMOs in mothers' milk on the height or length of breastfed children. These results are presented in **Table 1**. There was a significant positive correlation between the height/length of children and four HMOs, namely, 3FL for all mothers combined and secretor mothers but not nonsecretor mothers; DSLNT for nonsecretor mothers only; DFLac for secretor mothers and nonsecretor mothers; and 3'SL for all mothers combined, secretor mothers and nonsecretor mothers. There was a significant negative

correlation between heigh/length in children for 8 HMOs, namely, 6'SL, LSTc and DSLNH for all mothers combined; secretor mothers and non-secretor mothers; LNnT, LNH, FLNH for all mothers combined and secretor mothers; LNFP I for all mothers combined; and FDSLNH for nonsecretor mothers only. However, there was no significant correlation between the height or length of infants and children of all mothers and the diversity of 7 out of 19 HMOs, total HMOs, HMO-bound sialic acid, HMO-bound fucose, regardless of the secretor status.

Correlations between HMO concentrations and height according to sex

There were differences between male and female children of secretor and nonsecretor mothers in terms of the correlation of specific HMOs with height (**Table 2**). First, there was a significant positive correlation between height and 3FL in only female children and DFLac in only male children of secretor but not nonsecretor mothers; and between height and DSLNT in only female children of nonsecretor mothers. Second, there were significant negative correlations between height and LNT, LNnT and HMO-bound fucose in female children and between FLNH and DSLNH in male children of secretor mothers. Third, there was a significant negative correlation with 6'SL in both male and female children of secretor mothers and nonsecretor mothers; with LSTc in both male and female children of secretor mothers but only in male children of nonsecretor mothers; and with DFLNH in male children of nonsecretor mothers. Finally, LNT and HMO-bound fucose did not significantly correlate with height in the children of all mothers combined, regardless of secretor status, when the children were not stratified by sex (**Table 1**). However, when children were stratified by sex, LNT and fucose-bound HMOs had a significant negative correlation with height for only female children of secretor mothers (**Table 2**).

Correlations between HMO concentrations and weights of all children

We undertook Spearman's correlation analysis to assess the association of specific HMOs in mothers' milk with the weight of breastfed children (**Table 3**). There was a significant positive

correlation between 3'SL and the weight of children of all mothers combined, nonsecretor mothers, and between DFLac and the weight of children of secretor mothers. In contrast, there were significant negative correlations between LNnT, LNH, and FLNH and the weights of children of all mothers combined and secretor mothers. Similarly, 6'SL, LSTc, and DSLNH correlated negatively with the weights of children of all mothers combined, with secretor and nonsecretor mothers. However, there were no correlations between total HMOs, HMO-bound sialic acid, or HMO-bound fucose, and weight of the children of mothers, regardless of their secretor status.

Correlations between HMO concentrations and weights of male and female children

There were differences between male and female children of secretor and nonsecretor mothers in terms of the correlation of specific HMOs with weight (Table 4). First, there was a significant positive correlation between weight in male children and DFLac levels in secretor mothers; between weight in male children and LSTb levels in nonsecretor mothers, and between weight in female children and DSLNT levels in nonsecretor mothers. In contrast, there was a significant negative correlation between weight in male children and FLNH levels in secretor mothers, between weight in male children and DFLNH and 2'FL levels in nonsecretor mothers, and between weight in female children and LNFPI levels in nonsecretor mothers. Third, there was a negative correlation between weight and 6'SL in male children of secretor mothers and in both male and female children of nonsecretor mothers; between weight and LSTc in both male and female children of secretor mothers and in only female children of nonsecretors; and between DSLNH in both male and female children of secretor mothers and in only male children of nonsecretor mothers. Finally, 5 HMOs had no significant correlation with weight in children of all mothers combined, regardless of secretor status, when children were not grouped by sex (Table 3). However, when the children were grouped by sex, these HMOs had significant sex-dependent correlations with weight in children of nonsecretor mothers; 2'FL and DFLNH had significant negative, and LSTb had a significant positive correlation correlations in male children; LNFP I

and DSLNT had a significant negative and positive correlation in female children respectively (Table 4).

Associations between HMO concentrations and LAZ/HAZ scores for all children

Children were categorized as short, normal, or tall based on length/height for age-adjusted z (LAZ/HAZ) scores. The relationship between childrens height/length and median concentrations of HMOs in their mothers' milk were compared by Kruskall-Wallis and Mann–Whitney U tests. There were significant differences in the median milk concentrations of 7 HMOs and total HMOs fed to short, normal and tall children of all mothers combined, secretor and nonsecretor mothers according to the Kruskal–Wallis test (Figure 1 and Supplemental file 1). According to pairwise comparisons via the Mann–Whitney U test, compared with tall children, short- and normal-height children of all mothers combined were fed significantly greater concentrations of 3FL and DFLac. In contrast, the tall children of all mothers combined and secretor mothers were fed significantly higher concentrations of 6'SL and LSTc compared to short children of similar mothers; the tall children of secretor mothers were fed significantly greater concentrations of DFLNH and DSLNH than were the short children of similar mothers; and the tall children of nonsecretor mothers were fed significantly greater concentrations of DFLNH and DSLNH than were the short children of similar mothers; and the tall children of nonsecretor mothers were fed significantly greater concentrations of DFLNH and Supplemental file 1).

Associations between HMO concentrations and WAZ scores in all children

Breastfed children were categorized as underweight, normal or overweight for all mothers combined, and secretor mothers based on weight-for-age-adjusted (WAZ) z scores. There were only two underweight children among the nonsecretor group of mothers. Therefore, comparisons of HMO concentrations were made between all mothers and secretor mothers of underweight, normal and overweight children and between nonsecretor mothers of normal weight and overweight children by the Kruskal–Wallis test and Mann–Whitney U test, respectively (**Figure**

2, panel A). The underweight, normal and overweight children of all mothers combined, secretor mothers and nonsecretor mothers were fed significantly different concentrations of 6'SL, LSTc, and LNnT. According to pairwise comparisons, overweight children of all mothers combined, and secretor mothers were fed a significantly higher median concentration of 6'SL and LSTc than were normal weight and underweight children. Lastly, overweight children of secretor mothers were fed a significantly greater median concentration of LNnT compared to underweight children. There were no significant differences in the concentrations of 6'SL, LSTc, or LNnT fed to normal or overweight children of non-secretor mothers, probably because of the small sample sizes of the subcategories.

Association of HMO concentrations with WHZ scores in all children

Underweight, normal and overweight children of all mothers combined, and secretor but not nonsecretor mothers were fed significantly different concentrations of 3FL (**Figure 2, panel B**). Compared with overweight children, normal weight children of secretor mothers were fed a significantly greater concentration of 3FL. None of the other HMOs had any significant association with the WHZ score.

Associations between HMO concentrations and LAZ scores in male and female children

A significantly lower 6'SL concentrations were observed in mothers of short- and normal-height female children than in mothers of tall female children (**Figure 3**). No significant differences were detected in mothers of male children. In contrast, significant differences in the LSTc concentration were observed between mothers of both female and male children. According to pairwise comparisons, significantly lower concentrations of LSTc were observed in mothers of short male and female children than in mothers of tall male and female children. The difference in LSTc concentrations between mothers of short- and normal-height children was observed only in mothers of male children. Notably, 5 HMOs and total HMOs, which were significantly associated

with LAZ subcategories in all the children considered together, as shown in Figure 1, did not show any associations when the data were reanalyzed by sex.

Associations between HMO concentrations and WAZ scores in male and female children

First, significantly higher concentrations of 3FL, LNFP II, and FDSLNH were observed in mothers of underweight male children than in mothers of overweight male children (**Figure 3**). No significant differences in these HMOs were observed between mothers of underweight and overweight female children. Second, significantly higher concentrations of 6'FL and DSLNH were observed in mothers of overweight female children compared to those in mothers of underweight female children. Notably, associations with WAZ subcategories were observed only for LNFPII, FDSLNH and DSLNH when the data were analyzed by sex but not when all the children were considered together.

Association between HMO concentrations and WHZ scores in male and female children

Significantly higher concentrations of LNnT and LNT were observed in secretor mothers of overweight female children compared to those in secretor mothers of underweight and, for LNT, normal weight female children (Figure 3). No significant differences in both HMOs were observed between the secretor mothers of male children. Significantly higher concentrations of LNFP II and FDSLNH were observed in secretor mothers of underweight and overweight male children (Figure 3). No significant differences in either HMO were observed between secretor mothers of female children. The associations with WHZ subcategories were observed only for LNnT, LNT, LNFPII, and FDSLNH when the data were analyzed by sex but not when all the children were considered together. Notably, 3FL, which was significantly associated with the WHZ subcategory in mothers of secretor children, did not significantly differ between males and females, probably because of the small sample sizes when the data were subcategorized by sex.

Discussion

The World Health Organization recommends breastfeeding children for up to 2 years of age for healthy growth and development since human milk contains nutrients, growth factors, and immunological factors required for healthy growth and development [32]. HMOs constitute the third most abundant component of human milk after lactose and lipids, and provide protection against infections and affect growth and cognitive development in breastfed children [1]. Here, we report that in human milk samples collected from breastfeeding Ugandan mothers at a single time point postpartum, representing a wide range of lactation durations spanning 3-103 weeks, differences in the composition and concentrations of HMOs were associated with differences in the height and weight of their breastfed children. We also report for the first time that the association between some HMOs and growth depends on the sex of the children in addition to maternal secretor status.

There were positive or negative Spearman correlations between concentrations of specific HMOs and the heights and weights of children depending on the mothers' secretor status. Higher concentrations of specific HMOs were fed to children with different height (LAZ) or weight (WAZ and WHZ) categories depending on mothers' secretor status. Tall stature was associated with higher concentrations of 6'SL, LSTc, DFLNH, DSLNH, LNnT and total HMOs in secretor or nonsecretor mothers; short stature was associated with higher concentrations of 3'FL and DFLac; overweight children of secretor and nonsecretor mothers were fed on higher concentrations of 6'SL, LSTc and LNnT, respectively; and normal weight-for-length (WHZ) was associated with higher concentrations of 3'FL in human milk. Some HMOs had significant correlations with height or weight but showed no significant associations when these growth measurements were transformed into LAZ and WAZ scores; the lack of significance is probably due to the small sample size of mother–child pairs. Finally, the associations between specific HMOs and height and weight or LAZ, WAZ and WFL subcategories significantly differed between male and female

children depending on mothers' secretor status, suggesting sexual dimorphism in HMO-induced growth. Sex differences in the gut microbiota composition have been reported in children under 5 years old [33], but there is a dearth of information about sex-specific metabolism of HMOs by the gut microbiota. To the best of our knowledge, no previous studies have reported sex differences in the association between HMOs and growth.

Similar studies in the USA and Europe demonstrated an association between HMO concentrations or uptake and growth in children, with 2'FL being positively associated with and LNnT and LNFPI being negatively associated with children's height and weight [20,21,22]. These studies did not report sex differences. In our Ugandan mother-child pairs, 2'FL and LNFP I-secretor-dependent HMOs did not have a significant effect on weight in children of secretor mothers but were negatively correlated with weight in children of nonsecretor mothers. A Gambian study that analyzed the HMO composition and infant gut microbiota of mother-infant pairs at 4, 16 and 20 weeks after delivery demonstrated that LNFPI was predictive of the HAZ score at 20 weeks, while 3'SL was predictive of infant WAZ score [23]. In a Malawian study, milk samples were collected at a single time point at 6 months postpartum, after which the growth and development endpoints were longitudinally monitored for more than one year [24]. There was a positive association between the total abundance of HMOs and the change in LAZ from 6 to 12 months and between total HMOs, HMO-bound fucose and sialic acid and language development at 18 months among secretors. Whereas in the Gambian study, LNFPI + LNFPIII was predictive of HAZ, in our study, 6'SL, LSTc and three other HMOs and total HMOs were significantly associated with increased HAZ (tall stature). Again, unlike in the Gambian study, 3'SL was not associated with growth in Ugandan infants and children, but 3'FL was negatively associated with WHZ. Our study identified 6'SL and LSTc as important determinants of HAZ, which were not reported in Gambian children. In the Malawian study, 6'SL and 3'SL were negatively and positively associated with changes in the head circumference Z score. Our study did not measure head circumference. The Gambian

study highlighted the effect of season with higher HMO production during the dry season. Our study measured HMOs in human milk collected at a single time point at the beginning of the rainy season, but the mothers were not longitudinally followed up. The differences in outcomes between our study and those of the Gambian, Malawian, and Western studies might be due to differences in study designs and populations, diets, seasons of study, and geography.

Although numerous studies have reported significant associations between specific HMOs and the height and weight of breastfeeding children [20,21,22,23,24], none of the studies have reported differences in these associations between male and female children. In this study, stratifying the data by sex revealed significant associations between height and weight and specific HMOs in male and female children, which would otherwise have remained obscured. HMO-bound fucose and seven HMOs, 2'FL, LNFP I, 3FL, DFLNH, DSLNT, LNT and LSTb, exhibited significant associations in male or female children of secretor or nonsecretor mothers only when the data were disaggregated by sex. Our data suggest that maternal secretor status and the sex of breastfeeding children are important factors that must be considered when assessing the association between HMOs and growth measurements.

The mechanisms by which HMOs affect infant stature and weight in general and in a sex-specific manner in particular are not clear given the observational nature of our study. We hypothesize that differences in the microbiota composition between male and female children of secretor and nonsecretor mothers may lead to the observed sex differences in the association between HMOs and growth parameters. First, it has been speculated that HMOs affect growth through prevention of morbidity [24] since HMOs promote specific microbiota whose metabolites directly modulate immune functions [28,34]. It is plausible that, in our study population, HMOs affected children's growth through microbiota-induced modulation of immunity, which reduced morbidity and thereby promoted changes in HAZ, WAZ and WHZ scores, as proposed [35]. Second, the associations between maternal secretor status and infant microbiota composition [35,36] and Page 15 of 35

between infant microbiota and infant growth [25] may explain the observed differences in the associations between some HMOs and weight and height in children of secretor and nonsecretor mothers. Finally, there are sex differences in the gut microbiota composition of male and female children under 5 years old [33,38,39,40,41], which probably determines how the microbiota and HMOs interact to regulate growth in male and female Uganda children. These hypotheses should be tested in hypothesis-driven mechanistic longitudinal studies of mother–child pairs and randomized controlled clinical trials of commercially available HMOs used as food supplements. The outcomes of these studies may inform HMO combinations that can be used as food supplements for African children who may not enjoy the nutritional benefits of breastfeeding and the design of clinical trials assessing the growth and immunological effects of HMO supplementation.

This study has several limitations. First, the small sample size and the observational nature of the study did not allow us to perform statistical modeling to adjust for potential confounders (e.g., complementary feeding, maternal age and BMI, mode of delivery) or to perform multiple correction tests. The mode of delivery was probably not an important confounder since there were practically no Caesarian sections among the Ugandan mothers. Second, the collection of human milk at only one time point could have missed important changes in HMO composition during lactation [42,43]. However, we believe that our study cross-sectionally captured HMO compositional changes during lactation because the mothers represented a range of lactation stages from 3 to 103 weeks, which is greater than what has been reported in other similar studies. Third, anthropometric measurements in children were carried out at a single time point during sample collection, and the lack of serial measurements made it impossible to assess causal relationships between growth velocity and various HMOs. Fourth, the study did not collect fecal samples for analysis of microbiota composition and therefore cannot mechanistically link the observed children's growth outcomes to the effect of HMOs on microbiota composition. Finally,


information about feeding practices was not collected for the Ugandan children in this study, yet diet may affect the interaction between sex and the microbiota [33,41].

This study has several strengths despite its cross-sectional nature. First, for the first time, we demonstrated sexual dimorphism in the relationship between specific HMOs and growth parameters in children. These sex differences were discovered via post hoc analyses and remain to be investigated in future mechanistic studies. These studies could inform future nutritional interventions involving combinations of HMOs as food supplements that are equally effective for both male and female children. Second, this study examined the association between HMOs and growth in a wider range of children's ages and lactation durations than did previous studies. Finally, the weights and heights of the children and mothers were not self-reported but were measured by trained research staff using calibrated standard equipment.

Perspective and Significance

Our observational study demonstrated for the first time sex differences in the association between high concentrations of some HMOs and stature and weight in Ugandan children of secretor and nonsecretor mothers. Our study highlights the usefulness of analyzing these associations using data grouped by sex since considering sex-disaggregated data revealed an association with several HMOs, which was not evident otherwise. The sex differences were not detected during post hoc analyses and must be validated through hypothesis-driven mechanistic longitudinal studies of HMO concentrations and intake and growth in mother-child pairs, as well as randomized controlled trials of commercially available HMOs as food supplements in children. These validation studies should factor the interactions between maternal secretor status and the sex of breastfeeding children as important covariates. We believe that if validated, these results may be generalizable to breastfeeding infants and children in other countries and may inform sex-specific nutritional interventions that employ combinations of HMOs as infant food supplements.

Abbreviations:



3'SL, 3'sialyllactose

6'SL, 6'sialyllactose

DFlLac, difucosyllactose

DFLNH, Difucosyllacto-N-hexaose

DFLNT, Difucosyllacto-N-tetrose

DSLNH, disialyllacto-N-tetraose.

DSLNT, Disialyllacto-N-tetraose

FDSLNH, Fucosyldisialyllacto-N-hexaose

FLNH, Fucosyllacto-N-hexaose

LNFPI, lacto-N-fucopentaose I

LNFPII, lacto-N-fucopentaose II

LNFPIII, lacto-N-fucopentaose III

LNH, Lacto-N-hexaose

LNnT, Lacto-N-neotetraose

LNT, Lacto-N-tetraose

LSTb, Sialyllacto-*N*-tetraose b

LSTc, sialyllacto-N-tetraose c

Declarations

Ethical consideration: The Uganda National Council for Science and Technology and the

Research Ethics Committee of the Vector Division, Ministry of Health, approved the original

HD4MC study. All mothers who donated milk samples and brought infants to the study clinic for

weight and height measurements and health assessment signed or thumb-printed an informed

consent form.

Consent for publication: Not applicable.

Availability of data and materials: The datasets supporting the conclusion of this article will be

made available upon request from TGE.

Competing interest: The authors have no competing interest to disclose.

Funding: Thomas Egwang received funding from the Global Innovation Fund, and Grand

Challenges Canada. The funders played no role in the study design, data collection and analysis,

preparation of the manuscript or decision to publish this paper.

Authors' contributions: TJO and EO conducted the study, including sample collection; TJO drafted the manuscript; SM and CY performed the HMO laboratory analysis; VIM performed the statistical analysis; TGE and LB conceived and directed the study. All the authors read and approved the final manuscript.

Acknowledgments: We are very grateful to the Ugandan mother-child pairs for their participation. We would like to thank the clinical and laboratory staff of Med Biotech Laboratories at St Anne HC III Usuk, Katakwi, Uganda.

Authors Information: LB is University of California San Diego Chair of Collaborative Human Milk Research endowed by the Family Larsson-Rosenquist Foundation (FLRF), Switzerland.

Corresponding author: Tonny Jimmy Owalla; owalla:owallatonny@gmail.com. Current Affiliation: Department of Global Health, University of Washington, 3980 15th Ave NE, Box 351620, Seattle, WA 98195, USA.

References

- 1. Ballard O, Morrow AL. Human milk composition: nutrients and bioactive factors. Pediatr Clin North Am [Internet]. 2013 Feb [cited 2024 Jan 10];60(1):49–74. Available from: https://pubmed.ncbi.nlm.nih.gov/23178060/
- 2. Sankar MJ, Sinha B, Chowdhury R, Bhandari N, Taneja S, Martines J, et al. Optimal breastfeeding practices and infant and child mortality: a systematic review and meta-analysis. Acta Paediatr [Internet]. 2015 Dec 1 [cited 2024 Jan 10];104(467):3–13. Available from: https://pubmed.ncbi.nlm.nih.gov/26249674/
- Garwolińska D, Namieśnik J, Kot-Wasik A, Hewelt-Belka W. Chemistry of Human Breast Milk-A Comprehensive Review of the Composition and Role of Milk Metabolites in Child Development. J Agric Food Chem [Internet]. 2018 Nov 14 [cited 2024 Jan

- 10];66(45):11881–96. Available from: https://pubmed.ncbi.nlm.nih.gov/30247884/
- 4. Bode L. The functional biology of human milk oligosaccharides. Early Hum Dev [Internet].

 2015 Nov 1 [cited 2024 Jan 10];91(11):619–22. Available from:

 https://pubmed.ncbi.nlm.nih.gov/26375354/
- 5. Bode L, Jantscher-Krenn E. Structure–function relationships of human milk oligosaccharides. Adv Nutr [Internet]. 2012 May [cited 2024 Jan 10];3(3). Available from: https://pubmed.ncbi.nlm.nih.gov/22585916/
- 6. Ayechu-Muruzabal V, van Stigt AH, Mank M, Willemsen LEM, Stahl B, Garssen J, et al. Diversity of Human Milk Oligosaccharides and Effects on Early Life Immune Development. Front Pediatr [Internet]. 2018 [cited 2024 Jan 10];6. Available from: https://pubmed.ncbi.nlm.nih.gov/30250836/
- 7. Kong C, de Jong A, de Haan BJ, Kok J, de Vos P. Human milk oligosaccharides and nondigestible carbohydrates reduce pathogen adhesion to intestinal epithelial cells by decoy effects or by attenuating bacterial virulence. Food Res Int [Internet]. 2022 Jan 1 [cited 2024 Jan 10];151. Available from: https://pubmed.ncbi.nlm.nih.gov/34980402/
- 8. Weichert S, Jennewein S, Hüfner E, Weiss C, Borkowski J, Putze J, et al. Bioengineered 2'-fucosyllactose and 3-fucosyllactose inhibit the adhesion of *Pseudomonas aeruginosa* and enteric pathogens to human intestinal and respiratory cell lines. Nutr Res [Internet]. 2013

 Oct [cited 2024 Jan 10];33(10):831–8. Available from: https://pubmed.ncbi.nlm.nih.gov/24074741/
- 9. Bode L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology [Internet]. 2012 Sep [cited 2024 Jan 10];22(9):1147–62. Available from: https://pubmed.ncbi.nlm.nih.gov/22513036/

- 10. Newburg DS, Ruiz-Palacios GM, Morrow AL. Human milk glycans protect infants against enteric pathogens. Annu Rev Nutr [Internet]. 2005 [cited 2024 Jan 10];25:37–58. Available from: https://pubmed.ncbi.nlm.nih.gov/16011458/
- 11. Gao X, Wu D, Wen Y, Gao L, Liu D, Zhong R, et al. Antiviral effects of human milk oligosaccharides: A review. Int Dairy J [Internet]. 2020;110:104784. Available from: https://www.sciencedirect.com/science/article/pii/S0958694620301540
- 12. Newburg DS, Tanritanir AC, Chakrabarti S. Lactodifucotetraose, a human milk oligosaccharide, attenuates platelet function and inflammatory cytokine release. J Thromb Thrombolysis [Internet]. 2016 Jul 1 [cited 2024 Jan 10];42(1):46–55. Available from: https://pubmed.ncbi.nlm.nih.gov/26743063/
- 13. He YY, Liu SB, Kling DE, Leone S, Lawlor NT, Huang Y, et al. The human milk oligosaccharide 2'-fucosyllactose modulates CD14 expression in human enterocytes, thereby attenuating LPS-induced inflammation. Gut [Internet]. 2016 Jan 1 [cited 2024 Jan 10];65(1):33–46. Available from: https://pubmed.ncbi.nlm.nih.gov/25431457/
- 14. Goehring KC, Marriage BJ, Oliver JS, Wilder JA, Barrett EG, Buck RH. Similar to Those Who Are Breastfed, Infants Fed a Formula Containing 2'-Fucosyllactose Have Lower Inflammatory Cytokines in a Randomized Controlled Trial. J Nutr [Internet]. 2016 Dec 1 [cited 2024 Jan 10];146(12):2559–66. Available from: https://pubmed.ncbi.nlm.nih.gov/27798337/
- 15. Pisa E, Traversa A, Caputo V, Ottomana AM, Hauser J, Macrì S. Long-term consequences of reduced availability and compensatory supplementation of sialylated HMOs on cognitive capabilities. Front Cell Neurosci [Internet]. 2023 Jan 30 [cited 2024 Jan 10];17. Available from: https://pubmed.ncbi.nlm.nih.gov/36794260/

- 16. Liu F, Simpson AB, D'Costa E, Bunn FS, van Leeuwen SS. Sialic acid, the secret gift for the brain. Crit Rev Food Sci Nutr [Internet]. 2023 [cited 2024 Jan 10];63(29):9875–94. Available from: https://pubmed.ncbi.nlm.nih.gov/35531941/
- 17. Pisa E, Martire A, Chiodi V, Traversa A, Caputo V, Hauser J, et al. Exposure to 3'Sialyllactose-Poor Milk during Lactation Impairs Cognitive Capabilities in Adulthood. Nutrients [Internet]. 2021 Dec 1 [cited 2024 Jan 10];13(12). Available from: https://pubmed.ncbi.nlm.nih.gov/34959743/
- 18. Berger PK, Ong ML, Bode L, Belfort MB. Human Milk Oligosaccharides and Infant Neurodevelopment: A Narrative Review. Nutrients [Internet]. 2023 Feb 1 [cited 2024 Jan 10];15(3). Available from: https://pubmed.ncbi.nlm.nih.gov/36771425/
- Dinleyici M, Barbieur J, Dinleyici EC, Vandenplas Y. Functional effects of human milk oligosaccharides (HMOs). Gut Microbes [Internet]. 2023 [cited 2024 Jan 10];15(1).
 Available from: https://pubmed.ncbi.nlm.nih.gov/36929926/
- 20. Lagström H, Rautava S, Ollila H, Kaljonen A, Turta O, Mäkelä J, et al. Associations between human milk oligosaccharides and growth in infancy and early childhood. Am J Clin Nutr [Internet]. 2020 Apr 1 [cited 2024 Jan 10];111(4):769–78. Available from: https://pubmed.ncbi.nlm.nih.gov/32068776/
- 21. Alderete TL, Autran C, Brekke BE, Knight R, Bode L, Goran MI, et al. Associations between human milk oligosaccharides and infant body composition in the first 6 mo of life.

 Am J Clin Nutr [Internet]. 2015 Dec 1 [cited 2024 Jan 10];102(6):1381–8. Available from: https://pubmed.ncbi.nlm.nih.gov/26511224/
- 22. Saben JL, Sims CR, Abraham A, Bode L, Andres A. Human Milk Oligosaccharide Concentrations and Infant Intakes Are Associated with Maternal Overweight and Obesity

- and Predict Infant Growth. Nutrients [Internet]. 2021 Feb 1 [cited 2024 Jan 10];13(2):1–16. Available from: https://pubmed.ncbi.nlm.nih.gov/33572881/
- 23. Davis JCC, Lewis ZT, Krishnan S, Bernstein RM, Moore SE, Prentice AM, et al. Growth and Morbidity of Gambian Infants are Influenced by Maternal Milk Oligosaccharides and Infant Gut Microbiota. Sci Rep. 2017 Jan;7:40466.
- 24. Jorgensen JM, Young R, Ashorn P, Ashorn U, Chaima D, Davis JCC, et al. Associations of human milk oligosaccharides and bioactive proteins with infant growth and development among Malawian mother-infant dyads. Am J Clin Nutr [Internet]. 2021 Jan 1 [cited 2024 Jan 10];113(1):209–20. Available from: https://pubmed.ncbi.nlm.nih.gov/33096556/
- 25. Ma J, Palmer DJ, Geddes D, Lai CT, Stinson L. Human Milk Microbiome and Microbiome-Related Products: Potential Modulators of Infant Growth. Nutrients [Internet]. 2022 Dec 1 [cited 2024 Jan 10];14(23). Available from: https://pubmed.ncbi.nlm.nih.gov/36501178/
- 26. Puccio G, Alliet P, Cajozzo C, Janssens E, Corsello G, Sprenger N, et al. Effects of Infant Formula With Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial. J Pediatr Gastroenterol Nutr [Internet]. 2017 Apr 1 [cited 2024 Jan 10];64(4):624–31. Available from: https://pubmed.ncbi.nlm.nih.gov/28107288/
- 27. Steenhout P, Sperisen P, Martin F, Sprenger N, Wernimont S, Pecquet S, et al. Term infant formula supplemented with human milk oligosaccharides (2' Fucosyllactose and lacto-N-neotetraose) shifts stool microbiota and metabolic signatures closer to that of breastfed infants. FASEB J. 2016;30:275–7.
- 28. Vandenplas Y, Berger B, Carnielli VP, Ksiazyk J, Lagström H, Luna MS, et al. Human Milk Oligosaccharides: 2'-Fucosyllactose (2'-FL) and Lacto-N-Neotetraose (LNnT) in Infant Formula. Nutrients [Internet]. 2018 Sep 1 [cited 2024 Jan 10];10(9). Available from:

https://pubmed.ncbi.nlm.nih.gov/30149573/

- 29. Owalla TJ, Okurut E, Apungia G, Ojakol B, Lema J, Murphy SC, et al. Using the Ultrasensitive Alere Plasmodium falciparum Malaria Ag HRP-2TM Rapid Diagnostic Test in the Field and Clinic in Northeastern Uganda. Am J Trop Med Hyg [Internet]. 2020 Aug 1 [cited 2024 Jan 10];103(2):778–84. Available from: https://pubmed.ncbi.nlm.nih.gov/32602431/
- 30. Berger PK, Hampson HE, Schmidt KA, Alderete TL, Furst A, Yonemitsu C, et al. Stability of Human-Milk Oligosaccharide Concentrations Over 1 Week of Lactation and Over 6 Hours Following a Standard Meal. J Nutr [Internet]. 2023 Dec 1 [cited 2024 Jan 10];152(12):2727–33. Available from: https://pubmed.ncbi.nlm.nih.gov/36111739/
- 31. WHO. Department of Nutrition for Health and Development. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development [Internet]. 2006 [cited 2024 Jan 10]. p. 1–312. Available from: https://www.who.int/publications/i/item/924154693X
- 32. WHO; Fifty-fifth World Health Assembly (A55/15). Infant and young child nutrition Global strategy on infant and young child feeding Report by the Secretariat. 2002 [cited 2024 Jan 10];1–18. Available from: https://apps.who.int/gb/archive/pdf_files/WHA55/ea5515.pdf
- 33. Valeri F, Endres K. How biological sex of the host shapes its gut microbiota. Front Neuroendocrinol [Internet]. 2021 Apr 1 [cited 2024 Jan 10];61. Available from: https://pubmed.ncbi.nlm.nih.gov/33713673/
- 34. Triantis V, Bode L, van Neerven JRJ. Immunological Effects of Human Milk Oligosaccharides. Front Pediatr [Internet]. 2018 [cited 2024 Jan 10];6. Available from:

https://pubmed.ncbi.nlm.nih.gov/30013961/

- 35. McGuire MK, Meehan CL, McGuire MA, Williams JE, Foster J, Sellen DW, et al. What's normal? Oligosaccharide concentrations and profiles in milk produced by healthy women vary geographically. Am J Clin Nutr [Internet]. 2017 May 1 [cited 2024 Jan 10];105(5):1086–100. Available from: https://pubmed.ncbi.nlm.nih.gov/28356278/
- 36. Lewis ZT, Totten SM, Smilowitz JT, Popovic M, Parker E, Lemay DG, et al. Maternal fucosyltransferase 2 status affects the gut bifidobacterial communities of breastfed infants. Microbiome [Internet]. 2015 Apr 10 [cited 2024 Jan 10];3(1). Available from: https://pubmed.ncbi.nlm.nih.gov/25922665/
- 37. Liu F, Yan J, Wang X, Wang C, Chen L, Li Y, et al. Maternal Fucosyltransferase 2 Status Associates with the Profiles of Human Milk Oligosaccharides and the Fecal Microbiota Composition of Breastfed Infants. J Agric Food Chem [Internet]. 2021 Mar 17 [cited 2024 Jan 10];69(10):3032–43. Available from: https://pubmed.ncbi.nlm.nih.gov/33677972/
- 38. Solano-Aguilar G, Fernandez KP, Ets H, Molokin A, Vinyard B, Urban JF, et al. Characterization of fecal microbiota of children with diarrhea in 2 locations in Colombia. J Pediatr Gastroenterol Nutr [Internet]. 2013 May [cited 2024 Jan 10];56(5):503–11. Available from: https://pubmed.ncbi.nlm.nih.gov/23254448/
- 39. Kozyrskyj AL, Kalu R, Koleva PT, Bridgman SL. Fetal programming of overweight through the microbiome: boys are disproportionately affected. J Dev Orig Health Dis [Internet]. 2016 [cited 2024 Jan 10];7(1):25–34. Available from: https://pubmed.ncbi.nlm.nih.gov/26118444/
- 40. Martin R, Makino H, Yavuz AC, Ben-Amor K, Roelofs M, Ishikawa E, et al. Early-Life Events, Including Mode of Delivery and Type of Feeding, Siblings and Gender, Shape the

- Developing Gut Microbiota. PLoS One [Internet]. 2016 Jun 1 [cited 2024 Jan 10];11(6). Available from: https://pubmed.ncbi.nlm.nih.gov/27362264/
- 41. Kim YS, Unno T, Kim BY, Park MS. Sex Differences in Gut Microbiota. World J Mens Health [Internet]. 2020 Jan 1 [cited 2024 Jan 10];38(1):48–60. Available from: https://pubmed.ncbi.nlm.nih.gov/30929328/
- 42. Sprenger N, Lee LY, De Castro CA, Steenhout P, Thakkar SK. Longitudinal change of selected human milk oligosaccharides and association to infants' growth, an observatory, single center, longitudinal cohort study. PLoS One [Internet]. 2017 Feb 1 [cited 2024 Jan 10];12(2). Available from: https://pubmed.ncbi.nlm.nih.gov/28182762/
- 43. Plows JF, Berger PK, Jones RB, Alderete TL, Yonemitsu C, Najera JA, et al. Longitudinal Changes in Human Milk Oligosaccharides (HMOs) Over the Course of 24 Months of Lactation. J Nutr [Internet]. 2021 Apr 1 [cited 2024 Jan 10];151(4):876–82. Available from: https://pubmed.ncbi.nlm.nih.gov/33693851/

TABLE 1 Correlations between HMOs and the heights of all children¹

НМО	All, N=	- 111	Secretor,	, N= 88	Non Secretor, N= 23		
	Coef. (rho)	p value	Coef. (rho)	p value	Coef. (rho)	p value	
2'FL, nmol/mL	0.0135	0.8878	0.0996	0.3561	0.2584	0.2339	
3FL, nmol/mL	0.2490	0.0084	0.3149	0.0028	0.2371	0.2761	
LNnT, nmol/mL	-0.3169	0.0007	-0.4523	< 0.0001	0.0495	0.8226	
3'SL, nmol/mL	0.2883	0.0023	0.2312	0.0312	0.4786	0.0209	
DFLac, nmol/mL	0.1852	0.0517	0.3516	0.0008	0.4845	0.0191	
6'SL, nmol/mL	-0.4794	< 0.0001	-0.4375	< 0.0001	-0.7617	<0.0001	
LNT, nmol/mL	-0.1071	0.2631	-0.1424	0.1857	-0.1188	0.5893	
LNFP I, nmol/mL	-0.1934	0.0419	-0.1849	0.0846	-0.1222	0.5784	
LNFP II, nmol/mL	0.0895	0.3502	0.1623	0.1308	-0.1831	0.4030	
LNFP III, nmol/mL	0.0092	0.9235	-0.0312	0.7731	0.0208	0.9250	
LSTb, nmol/mL	0.1351	0.1576	0.0924	0.3921	0.2989	0.1659	
LSTc, nmol/mL	-0.4368	< 0.0001	-0.4208	< 0.0001	-0.5815	0.0036	
DFLNT, nmol/mL	-0.1663	0.0811	-0.1756	0.1018	0.1198	0.5862	
LNH, nmol/mL	-0.2768	0.0033	-0.2730	0.0101	-0.2722	0.2089	
DSLNT, nmol/mL	0.0355	0.7116	-0.0748	0.4887	0.4143	0.0494	
FLNH, nmol/mL	-0.2880	0.0022	-0.3209	0.0023	-0.0272	0.9019	
DFLNH, nmol/mL	-0.1372	0.1510	-0.1028	0.3407	-0.1331	0.5448	
FDSLNH, nmol/mL	-0.0681	0.4778	0.0591	0.5843	-0.4910	0.0174	
DSLNH, nmol/mL	-0.3827	< 0.0001	-0.3385	0.0013	-0.5588	0.0056	
Total HMO	-0.0174	0.8560	0.0600	0.5790	0.0460	0.8348	
Fuc HMO, nmol/mL	0.0513	0.5928	0.1876	0.0801	-0.1163	0.5972	
Sia HMO, nmol/mL	-0.0793	0.4080	-0.1029	0.3402	-0.0440	0.8418	
Diversity	-0.0914	0.3399	-0.1051	0.3300	-0.1133	0.6066	

¹ Coef (rho), Spearman's rank test correlation coefficient obtained after log transformation of HMO concentrations as the independent variable; the dependent variable (height) had a parametric distribution. HMO, human milk oligosaccharide. 2'FL, 2' fucosyllactose; see the abbreviation list for the rest of the HMOs. Fuc HMO, fucosylated human milk oligosaccharide. Sia HMO, sialylated human milk oligosaccharide. n, sample sizes.

TABLE 2 Correlations between HMOs and the height of female and male children¹

	Secretor				Non Secretor				
НМО .	Females (n= 47)		Males (n= 40)		Females (n= 11)		Males (n=12)		
	Coef. (rho)	p value	Coef. (rho)	p value	Coef. (rho)	p value	Coef. (rho)	p value	
2'FL, nmol/mL	0.1737	0.2430	0.0303	0.8527	0.2979	0.3736	0.0498	0.8779	
3FL, nmol/mL	0.4005	0.0053	0.2437	0.1297	-0.0250	0.9419	0.1811	0.5732	
LNnT, nmol/mL	-0.5562	<0.0001	-0.2883	0.0713	0.2299	0.4964	-0.3509	0.2635	
3'SL, nmol/mL	0.2137	0.1492	0.2930	0.0703	0.4872	0.1286	0.2750	0.3871	
DFLac, nmol/mL	0.2246	0.1291	0.4611	0.0027	0.4304	0.1864	0.3831	0.2190	
6'SL, nmol/mL	-0.3975	0.0057	-0.5274	0.0005	-0.7246	0.0117	-0.7933	0.0021	
LNT, nmol/mL	-0.3080	0.0352	-0.0918	0.5733	-0.0547	0.8730	-0.4691	0.1239	
LNFP I, nmol/mL	-0.1460	0.3273	-0.2284	0.1562	-0.4457	0.1694	-0.0910	0.7784	
LNFP II, nmol/mL	0.0695	0.6425	0.2914	0.0681	-0.2462	0.4654	-0.0791	0.8069	
LNFP III, nmol/mL	-0.1152	0.4406	-0.0390	0.8114	0.1019	0.7656	-0.1949	0.5439	
LSTb, nmol/mL	-0.0116	0.9384	0.0491	0.7634	0.2104	0.5347	0.5138	0.0875	
LSTc, nmol/mL	-0.4559	0.0013	-0.4743	0.0020	-0.3705	0.2619	-0.5839	0.0462	
DFLNT, nmol/mL	-0.1489	0.3177	-0.2579	0.1082	-0.1314	0.7002	0.3825	0.2198	
LNH, nmol/mL	-0.2230	0.1320	-0.1719	0.2889	-0.1276	0.7085	-0.1633	0.6121	
DSLNT, nmol/mL	-0.1872	0.2077	-0.1687	0.2982	0.6266	0.0391	0.0876	0.7867	
FLNH, nmol/mL	-0.2597	0.0779	-0.4156	0.0076	0.0248	0.9424	-0.4388	0.1536	
DFLNH, nmol/mL	-0.0570	0.7036	-0.0814	0.6178	0.0078	0.9817	-0.5923	0.0424	
FDSLNH, nmol/mL	-0.0334	0.8235	0.2463	0.1255	-0.5878	0.0572	-0.0152	0.9626	
DSLNH, nmol/mL	-0.2857	0.0516	-0.3252	0.0406	-0.5064	0.1120	-0.3390	0.2810	
Total HMO	0.0850	0.5702	0.0113	0.9450	0.2820	0.4008	0.1113	0.7307	
Fuc HMO, nmol/mL	0.3094	0.0343	0.0976	0.5492	-0.2251	0.5058	0.0479	0.8824	
Sia HMO, nmol/mL	-0.2157	0.1453	-0.0522	0.7492	0.0083	0.9807	0.1133	0.7259	
Diversity	-0.2074	0.1619	-0.0539	0.7412	-0.2823	0.4003	0.0115	0.9717	

¹ Coef (rho), Spearman's rank test correlation coefficient obtained after log transformation of HMO concentrations as the independent variable; the dependent variable (height) had a parametric distribution. HMO, human milk oligosaccharide. 2'FL, 2' fucosyllactose; see the abbreviation list for the rest of the HMOs. Fuc HMO, fucosylated human milk oligosaccharide. Sia HMO, sialylated human milk Page 29 of 35

oligosaccharide. N, sample sizes; note that sample sizes for the male versus female subcategories for secretor and nonsecretor mothers were smaller, which probably explains why 3FL did not show a sex-dependent correlation.

TABLE 3 Correlations between HMOs and the weights of all children¹

НМО	All, N=	= 115	Secretor,	N= 90	Non Secretor, N= 25		
	Coef. (rho)	p value	Coef. (rho)	p value	Coef. (rho)	p value	
2'FL, nmol/mL	-0.0028	0.9762	0.1161	0.2756	0.0490	0.8162	
3FL, nmol/mL	0.1784	0.0565	0.1903	0.0724	0.2868	0.1646	
LNnT, nmol/mL	-0.2232	0.0165	-0.2467	0.0191	-0.2293	0.2703	
3'SL, nmol/mL	0.2848	0.0021	0.2005	0.0596	0.5192	0.0078	
DFLac, nmol/mL	0.0959	0.3078	0.2659	0.0113	0.3427	0.0935	
6'SL, nmol/mL	-0.4199	< 0.0001	-0.3470	0.0008	-0.7515	<0.0001	
LNT, nmol/mL	-0.0776	0.4095	0.4095	0.5743	-0.2767	0.1806	
LNFP I, nmol/mL	-0.1738	0.0633	-0.1333	0.2103	-0.1220	0.5612	
LNFP II, nmol/mL	0.0743	0.4298	0.0833	0.4349	0.0420	0.8421	
LNFP III, nmol/mL	-0.0069	0.9418	-0.0294	0.7833	-0.2487	0.2306	
LSTb, nmol/mL	0.1505	0.1084	0.1024	0.3369	0.2425	0.2429	
LSTc, nmol/mL	-0.4271	< 0.0001	-0.3972	0.0001	-0.5650	0.0033	
DFLNT, nmol/mL	-0.1571	0.0936	-0.1766	0.0959	0.1438	0.4929	
LNH, nmol/mL	-0.2468	0.0078	-0.2195	0.0376	-0.3560	0.0807	
DSLNT, nmol/mL	0.0508	0.5895	-0.0592	0.5793	0.3723	0.0669	
FLNH, nmol/mL	-0.2926	0.0015	-0.2882	0.0059	-0.2674	0.1964	
DFLNH, nmol/mL	-0.1487	0.1126	-0.1047	0.3259	-0.1313	0.5314	
FDSLNH, nmol/mL	-0.0896	0.3412	-0.0037	0.9721	-0.3513	0.0851	
DSLNH, nmol/mL	-0.4155	< 0.0001	-0.4004	0.0001	-0.4842	0.0142	
Total HMO	-0.0380	0.6869	0.0899	0.3995	-0.3155	0.1244	
Fuc HMO, nmol/mL	0.0161	0.8641	0.1522	0.1520	0.0101	0.9618	
Sia HMO, nmol/mL	-0.0928	0.3241	-0.1317	0.2159	-0.0878	0.6764	
Diversity	-0.1167	0.2142	-0.1141	0.2841	-0.2837	0.1694	

¹Coef (rho), Spearman's rank test correlation coefficient obtained after log transformation of HMO concentrations as the independent variable; the dependent variable (weight) had a parametric distribution. HMO, human milk oligosaccharide. 2'FL, 2' fucosyllactose; see the abbreviation list for the rest of the HMOs. Fuc HMO, fucosylated human milk oligosaccharide. Sia HMO, sialylated human milk oligosaccharide. n, sample sizes.

TABLE 4 Correlations between HMOs and the weights of female and male children¹

	Secretor				Non Secretor			
имо	Females (n=48)		Males (n= 41)		Females (n= 12)		Males (n=13)	
HMO -	Coef.	p value	Coef.	p value	Coef.	p value	Coef.	p value
	(rho)		(rho)		(rho)		(rho)	
2'FL, nmol/mL	0.1574	0.2854	0.0441	0.7844	0.3546	0.2591	-0.6247	0.0250
3FL, nmol/mL	0.1547	0.2937	0.1968	0.2175	0.4043	0.1936	0.0112	0.9727
LNnT, nmol/mL	-0.2042	0.1639	-0.2651	0.0939	-0.2695	0.3973	-0.3166	0.2891
3'SL, nmol/mL	0.1590	0.2803	0.2165	0.1796	0.5391	0.0751	0.1485	0.6250
DFLac, nmol/mL	0.1916	0.1920	0.3263	0.0374	0.4610	0.1340	0.1457	0.6317
6'SL, nmol/mL	-0.2672	0.0664	-0.4934	0.0010	-0.7164	0.0113	-0.6696	0.0145
LNT, nmol/mL	-0.0215	0.8849	-0.0785	0.6256	-0.5249	0.0842	-0.3642	0.2195
LNFP I, nmol/mL	-0.0336	0.8205	-0.2116	0.1841	-0.6029	0.0423	-0.1793	0.5540
LNFP II, nmol/mL	-0.0444	0.7647	0.1925	0.2278	0.0567	0.8676	0.0280	0.9285
LNFP III, nmol/mL	-0.1886	0.1992	0.0403	0.8026	-0.2624	0.4091	-0.4286	0.1441
LSTb, nmol/mL	0.1742	0.2365	0.1020	0.5257	0.0780	0.8138	0.6107	0.0293
LSTc, nmol/mL	-0.3873	0.0065	-0.4769	0.0016	-0.5887	0.0484	-0.2914	0.3306
DFLNT, nmol/mL	-0.1549	0.2930	-0.1809	0.2577	0.3972	0.2029	0.2157	0.4749
LNH, nmol/mL	-0.2749	0.0586	-0.1718	0.2829	-0.3688	0.2393	-0.2830	0.3452
DSLNT, nmol/mL	-0.0508	0.7319	-0.0907	0.5728	0.6384	0.0298	0.1541	0.6119
FLNH, nmol/mL	-0.2135	0.1451	-0.3495	0.0251	-0.3192	0.3116	-0.4931	0.0887
DFLNH, nmol/mL	-0.0380	0.7978	-0.1115	0.4875	-0.1208	0.7087	-0.6298	0.0236
FDSLNH, nmol/mL	-0.1766	0.2298	0.1484	0.3545	-0.4610	0.1340	0.0953	0.7552
DSLNH, nmol/mL	-0.3830	0.0072	-0.4711	0.0019	-0.4681	0.1283	-0.6247	0.0250
Total HMO	0.1369	0.3534	-0.0108	0.9467	-0.0709	0.8325	-0.2774	0.3552
Fuc HMO, nmol/mL	0.1632	0.2678	0.0689	0.6687	0.1419	0.6629	0.0841	0.7835
Sia HMO, nmol/mL	-0.2127	0.1466	-0.1074	0.5039	-0.1844	0.5676	0.1625	0.5923
Diversity	-0.1382	0.3489	-0.0829	0.6063	-0.2558	0.4201	-0.3203	0.2830

¹Coef (rho), Spearman's rank test correlation coefficient obtained after log transformation of HMO concentrations as the independent variable; the dependent variable (weight) had a parametric distribution. HMO, human milk oligosaccharide. 2'FL, 2' fucosyllactose; see the abbreviation list

for the rest of the HMOs. Fuc HMO, fucosylated human milk oligosaccharide. Sia HMO, sialylated human milk oligosaccharide. n, sample sizes; note that sample sizes for the male versus female subcategories for secretor and nonsecretor mothers were smaller, which probably explains why LNH, LNnT and 3'SL did not show sex-dependent correlations.

Figure legends

respectively. NS, nonsignificant; * P < 0.05.

FIGURE 1 Association between HMO concentrations and LAZ/HAZ scores for all children. S, short children; N, normal-height children; T, tall children. HMO abbreviations are indicated in the list of abbreviations. The data are shown as box and whisker plots with the medians and the lower and upper quartiles or interquartile range (IQR). P values represent the outcomes of comparisons of the three and two LAZ subcategories according to the Kruskal–Wallis and Mann–Whitney U tests, respectively. NS, nonsignificant; *P < 0.05; **P < 0.01; ***P < 0.001.


FIGURE 2 Association between HMO concentrations and WAZ/WHZ scores in all children. U, underweight children; N, normal weight children; O, overweight children. Panel A: HMOs and WAZ. Panel B: HMOs and WHZ. HMO abbreviations are indicated in the list of abbreviations. The data are shown as box and whisker plots with the medians and the lower and upper quartiles or interquartile range (IQR). P values represent the outcomes of comparisons of the three and two WAZ or WHZ subcategories according to the Kruskal–Wallis and Mann–Whitney U tests,

FIGURE 3 Association between HMO concentrations and LAZ/WAZ/WHZ scores in male and female children. U, underweight children; N, normal weight children; O, overweight children; F, females; M, males. HMO abbreviations are indicated in the list of abbreviations. The data are shown as box and whisker plots with the medians and the lower and upper quartiles or interquartile range (IQR). P values represent the outcomes of comparisons of two LAZ, WAZ or WHZ subcategories according to the Mann–Whitney U test. NS, nonsignificant; * P < 0.05; ** P < 0.01


Supplemental File 1 (pdf)

Title: Concentrations of HMOs in breast milk and LAZ subcategories in infants.

Description of the data: S, short; N, normal height children; T, tall children. The data are shown as box and whisker plots with the medians and the lower and upper quartiles or interquartile range (IQR). P values represent the outcomes of comparisons of the three and two LAZ subcategories according to the Kruskal–Wallis and Mann–Whitney U tests, respectively. NS, nonsignificant; * P < 0.05.



A. HMOs and WAZ



B. HMOs and WHZ

